PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 101 | 229-236
Article title

Acetylsalicylic acid in prevention of preeclampsia

Content
Title variants
Languages of publication
EN
Abstracts
EN
Preeclampsia is a frequent and dangerous complication of pregnancy. It is a significant cause of death for the mother and baby. In the course of this disease, the blood flow in the placenta is impaired, what leads to foetus hypoxia. It is characterized by high blood pressure and frequently large amount of protein in urine. To describe whether acetylsalicylic acid is effective in prevention of preeclampsia. Standard up-to-date criteria were followed for review of the literature data. A search for English-language articles in PubMed database was performed. Papers published in 2017 were reviewed. In double-blind trial published in 2017 in The New England Journal of Medicine researchers divided women who were at high risk for preeclampsia into two groups. One group was receiving acetylsalicylic acid and other was receiving placebo. Preeclampsia was observed in 1.6% participants in the acetylsalicylic acid group, compared with 4.3% in the placebo group. From other study we found out that acetylsalicylic acid has a dose-response effect. Greater reduction in the risk of preeclampsia was reported with the acetylsalicylic acid dosage >75 mg/d. When acetylsalicylic acid was included in treatment at >16 weeks, there was less reduction of preeclampsia without relationship with acetylsalicylic acid dosage. Other meta-analysis shows that there was no statistically significant difference in occurrence of preeclampsia between women who started taking acetylsalicylic acid before and after 16th week of pregnancy. Acetylsalicylic acid is a good agent to prevent of preeclampsia. It should be prescribed to women in high risk groups regardless of the duration of pregnancy even though it may not reduce the risk of preeclampsia as much as before 16th week of gestation.
Discipline
Year
Volume
101
Pages
229-236
Physical description
Contributors
  • Student Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Poland
author
  • Student Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Poland
  • Student Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Poland
  • Student Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Poland
  • Department of Human Anatomy, Chair of Human Anatomy, Medical University of Lublin, Poland
References
  • [1] Redman C, Sargent I. Pre-eclampsia, the Placenta and the Maternal Systemic Inflammatory Response—A Review. Placenta 2003, 24 Suppl A. S21-7.
  • [2] Litwińska E, Litwińska M, Oszukowski P, Szaflik K, Kaczmarek P. Combined screening for early and late pre-eclampsia and intrauterine growth restriction by maternal history, uterine artery Doppler, mean arterial pressure and biochemical markers. Advances in Clinical and Experimental Medicine 2017, 26. 439-448
  • [3] Müller-Deile J, Schiffer M. Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy. World Journal of Nephrology 2014;3(4):169-181.
  • [4] D’Souza R, Kingdom J. Preeclampsia. Canadian Medical Association Journal 2016; 188(16): 1178.
  • [5] Massaro AR, Lippp GYH. Stroke Prevention in Atrial Fibrillation: Focus on Latin America. Arquivos Brasileiros de Cardiologia 2016;107(6):576-589.
  • [6] Wei X, Walley JD, Zhang Z, et al. Implementation of a comprehensive intervention for patients at high risk of cardiovascular disease in rural China: A pragmatic cluster randomized controlled trial. Voskuil M, ed. PLoS ONE 2017;12(8):e0183169.
  • [7] Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. The BMJ 2016;355:i6188.
  • [8] Baena CP, D'Amico RC, Slongo H, Brunoni AR, Goulart AC, Benseñor I . The effectiveness of aspirin for migraine prophylaxis: a systematic review. Sao Paulo Med J. 2017 Jan-Feb; 135(1): 42-49.
  • [9] Goodlin RC, Haesslein HO, Fleming J. Aspirin for the treatment of recurrent toxemia. Lancet 1978; 2: 51.
  • [10] Tong S, Mol BW, Walker SP Preventing preeclampsia with aspirin: does dose or timing matter? Am J Obstet Gynecol. 2017 Feb; 216(2): 95-97. doi: 10.1016/j.ajog.2016.12.003.
  • [11] Roberge, S., Demers, S., Nicolaides, K. H., Bureau, M., Côté, S. and Bujold, E. (2016), Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol 47: 548–553.
  • [12] Xu TT, Zhou F, Deng CY, Huang GQ, Li JK, Wang XD.J Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. Clin Hypertens (Greenwich). 2015; 17: 567–573
  • [13] Yao S, Wu H, Yu Y. [Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. Nan Fang Yi Ke Da Xue Xue Bao. 2015 Jun; 35(6): 868-73.
  • [14] Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013 May; 41(5): 491-9.
  • [15] Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E, Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis. Fetal Diagn Ther 2012; 31: 141-146
  • [16] Cantu JA, Jauk VR, Owen J, Biggio JR, Abramovici AR, Edwards RK, Tita AT. Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy? J Matern Fetal Neonatal Med. 2015 Jul; 28(10): 1128-32.
  • [17] Trivedi N A. A meta-analysis of low-dose aspirin for prevention of preeclampsia. J Postgrad Med 2011; 57: 91-5
  • [18] Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. The BMJ. 2016; 353: i1753.
  • [19] Trapani A Jr, Goncalves LF, Trapani TF, Vieira S, Pires M, Pires MM. Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: a randomized controlled trial. Obstet Gynecol 2016; 128: 253-9.
  • [20] Cluver CA, Walker SP, Mol BW, et al. Double blind, randomized, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE trial): a study protocol. BMJ Open 2015; 5: e008211.
  • [21] Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 2016; 214: 356.e1-15.
  • [22] Brownfoot FC, Tong S, Hannan NJ, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension 2015; 66: 687-97.
  • [23] Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, et al. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol. 2016 Mar; 27(3): 903-13. doi: 10.1681/ASN.2015020157. Epub 2015 Sep 24.
  • [24] Daniel L. Rolnik, David Wright, Liona C. Poon, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia, N Engl J Med 2017; 377:613-622.
  • [25] Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30: 260-79.
  • [26] Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis, Am J Obstet Gynecol. 2017 Feb; 216(2): 110-120.e6.
  • [27] Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017 Feb; 216(2): 121-128.e2.
  • [28] World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. World Health Organization; 2011.
  • [29] Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews, 2007, (1): CD002252.
Document Type
short_communication
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-de617fef-d078-4dda-a5c7-88125636ed77
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.